Lomeguatrib and Temozolomide in Metastatic Colorectal Cancer
Author Information
Author(s): Khan O A, Ranson M, Michael M, Olver I, Levitt N C, Mortimer P, Watson A J, Margison G P, Midgley R, Middleton M R
Primary Institution: CR UK Medical Oncology Unit, Churchill Hospital, Oxford, UK
Hypothesis
To evaluate the tumour response to lomeguatrib and temozolomide administered for 5 consecutive days every 4 weeks in patients with metastatic colorectal carcinoma.
Conclusion
The combination of lomeguatrib and temozolomide is not effective in treating metastatic colorectal cancer.
Supporting Evidence
- None of the patients responded to treatment.
- Three patients had stable disease.
- Median time to progression was 50 days.
Takeaway
Doctors tried a new medicine combination to help people with advanced colon cancer, but it didn't work.
Methodology
Patients received lomeguatrib and temozolomide for 5 consecutive days every 4 weeks, and their responses were evaluated every two cycles.
Limitations
The study was closed early due to lack of responses, and the sample size was smaller than originally planned.
Participant Demographics
{"median_age":59,"gender_ratio":{"male":14,"female":5},"prior_chemotherapy":{"fluoropyrimidines":19,"irinotecan":15,"oxaliplatin":12}}
Statistical Information
Confidence Interval
47–60 days
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website